Our results indicated that disruption of tumor-cell intrinsic aggressiveness by systematic chemotherapies could not abolish overexpressed PD-L1 on aDTCs, thereby demonstrating that PD-L1+ aDTCs were still detectable in most post-therapy ascites in 5 of 33 enrolled patients (Fig. 1h). This evidence concerns the gene CD274 and neoplasm.